PE20001049A1 - Complejos estables de compuestos escasamente solubles - Google Patents

Complejos estables de compuestos escasamente solubles

Info

Publication number
PE20001049A1
PE20001049A1 PE1999000947A PE00094799A PE20001049A1 PE 20001049 A1 PE20001049 A1 PE 20001049A1 PE 1999000947 A PE1999000947 A PE 1999000947A PE 00094799 A PE00094799 A PE 00094799A PE 20001049 A1 PE20001049 A1 PE 20001049A1
Authority
PE
Peru
Prior art keywords
polymer
poorly soluble
weight
drying
refers
Prior art date
Application number
PE1999000947A
Other languages
English (en)
Inventor
Antonio A Albano
Navnit Hargovindas Shah
Harpreet K Sandhu
Wantanee Phuapradit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20001049(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001049A1 publication Critical patent/PE20001049A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPLEJO INSOLUBLE EN AGUA DE a)DE 0,1% A 80% EN PESO DE UN COMPUESTO ACTIVO ESTABLE, AMORFO; ESCASAMENTE SOLUBLE CUANDO ESTA EN LA FORMA CRISTALINA, CON UNA SOLUBILIDAD INFERIOR A 1 mg/ml EN SOLUCION ACUOSA; DE FORMULA I, TOLCAPONE, ACIDO 1,3-CISRETINOICO, SAQUINAVIR, ENTRE OTROS; b)NO MENOS DE 20% DE PESO DE UN POLIMERO IONICO INSOLUBLE EN AGUA QUE TIENE UN PESO MOLECULAR SUPERIOR A 80 000 D Y UNA TEMPERATURA DE TRANSICION VITREA IGUAL O SUPERIOR A 50°C; DE PREFERENCIA ES UN POLIMERO CATIONICO TAL COMO COPOLIMERO DE DIMETILAMINOETILMETACRILATO, ESTER METACRILICO NEUTRO; POLIMERO ANIONICO TAL COMO COPOLIMERO DE ACIDO METACRILICO, ENTRE OTROS; LA SOLUBILIDAD DEPENDE DEL pH; c)UN SOPORTE. TAMBIEN SE REFIERE A PROCEDIMIENTOS PARA LA PREPARACION QUE COMPRENDE a)DISOLUCION DE LA FORMA CRISTALINA DEL COMPUESTO Y DEL POLIMERO IONICO EN UN SOLVENTE ORGANICO COMO ALCOHOL ETILICO O METILICO, SULFOXIDO DE DIMETILO, ENTRE OTROS; b)PONER EN CONTACTO CON UN SOLUCION ACUOSA A UN pH EN EL QUE EL POLIMERO IONICO ES ESCASAMENTE SOLUBLE, MICROPRECIPITANDOSE EL COMPUESTO ACTIVO Y EL POLIMERO EN FORMA DE UN COMPLEJO COMPUESTO/POLIMERO, ELIMINANDOSE EL SOLVENTE MEDIANTE EL SECADO POR PULVERIZACION O LIOFILIZACION, EL DISOLVENTE RESIDUAL SE ELIMINA MEDIANTE EVAPORACION O SECADO
PE1999000947A 1998-09-22 1999-09-17 Complejos estables de compuestos escasamente solubles PE20001049A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
PE20001049A1 true PE20001049A1 (es) 2000-10-17

Family

ID=26798138

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000947A PE20001049A1 (es) 1998-09-22 1999-09-17 Complejos estables de compuestos escasamente solubles

Country Status (33)

Country Link
US (1) US6350786B1 (es)
EP (1) EP0988863B2 (es)
JP (5) JP2000095708A (es)
KR (1) KR100362019B1 (es)
CN (1) CN1201821C (es)
AR (2) AR022096A1 (es)
AT (1) ATE265232T1 (es)
AU (1) AU770745B2 (es)
BR (1) BR9904283A (es)
CA (1) CA2282906C (es)
CO (1) CO5140077A1 (es)
CZ (1) CZ300215B6 (es)
DE (1) DE69916733T3 (es)
DK (1) DK0988863T4 (es)
ES (1) ES2218918T5 (es)
HK (1) HK1026632A1 (es)
HR (1) HRP990287B1 (es)
HU (1) HU228341B1 (es)
ID (1) ID24034A (es)
IL (1) IL131957A (es)
MA (1) MA26692A1 (es)
MY (1) MY124377A (es)
NO (1) NO326928B1 (es)
NZ (1) NZ337884A (es)
PE (1) PE20001049A1 (es)
PL (1) PL202757B1 (es)
PT (1) PT988863E (es)
RS (1) RS50193B (es)
RU (1) RU2240827C2 (es)
SG (1) SG97131A1 (es)
SI (1) SI0988863T2 (es)
TR (1) TR199902324A3 (es)
TW (1) TWI234465B (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
AR033651A1 (es) * 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
JP4786113B2 (ja) * 2000-05-16 2011-10-05 オーソーマクニール ファーマシューティカル， インコーポレイテッド 超臨界二酸化炭素を用いる医療用装置のコーティング方法
US6482847B2 (en) 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
ES2305250T3 (es) * 2001-05-30 2008-11-01 Csir Procedimiento de encapsulacion de una sustancia activa.
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
ATE480226T1 (de) 2001-06-22 2010-09-15 Bend Res Inc Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere
DE60233874D1 (de) 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
RU2005103625A (ru) 2002-08-12 2005-08-20 Пфайзер Продактс Инк. (Us) Фармацевтические композиции полуупорядоченных лекарств и полимеров
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
CN100563658C (zh) 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
WO2005046697A1 (ja) * 2003-11-14 2005-05-26 Ajinomoto Co., Inc. フェニルアラニン誘導体の徐放性経口投与製剤
RU2411043C2 (ru) * 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
EP1839650A1 (en) * 2004-12-28 2007-10-03 Eisai R&D Management Co., Ltd. Quick disintegration tablet and method of producing the same
KR101238525B1 (ko) * 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
EP1885338A1 (en) * 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
BRPI0611863B1 (pt) * 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
US20080221047A1 (en) 2006-12-27 2008-09-11 Astellas Pharma Inc., Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
US20100222311A1 (en) * 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
AR078033A1 (es) * 2009-04-03 2011-10-12 Plexxikon Inc Una dispersion solida, que contiene al compuesto {3-[5-(4-(cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico, composiciones y formulaciones que comprenden a dicha dispersion solida; metodos para fabricar dicha dispersion solida, formas 1 y 2 de
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
CN103153306A (zh) * 2010-05-31 2013-06-12 安斯泰来制药有限公司 三唑化合物的固体分散体
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
US9457093B2 (en) 2011-10-14 2016-10-04 Array Biopharma Inc. Solid dispersions of a ERB2 (HER2) inhibitor
AU2013234921A1 (en) 2012-03-23 2014-10-02 Array Biopharma Inc. Treatment of brain cancer
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
RU2015123632A (ru) 2012-11-19 2017-01-10 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции ингибиторов сетр
RU2015128794A (ru) 2012-12-20 2017-01-25 КАШИВ ФАРМА, ЭлЭлСи Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
NZ708272A (en) 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
US20160213575A1 (en) * 2013-09-11 2016-07-28 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
KR20160093611A (ko) * 2013-12-05 2016-08-08 알라이즈 바이오시스템즈 게엠베하 경구 투여를 위한 약물 제제의 제조 방법
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
JP2018516262A (ja) * 2015-05-29 2018-06-21 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． イソトレチノインの経口医薬組成物
CA3041155C (en) 2016-12-13 2021-12-14 Nanjing Transthera Biosciences Co., Ltd. Multi-kinase inhibitor compound, and crystal form and use thereof
US11207324B2 (en) 2017-04-28 2021-12-28 Seagen Inc. Treatment of HER2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
CA3168667A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
KR20220129628A (ko) 2020-03-03 2022-09-23 데쿠세리아루즈 가부시키가이샤 화상 표시 장치의 제조 방법
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
PT83812B (en) * 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
NZ227850A (en) † 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ATE159426T1 (de) † 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
EP0784974B1 (en) * 1995-07-26 2003-05-21 Kyowa Hakko Kogyo Co., Ltd. preparation of xanthine derivatives in a solid dispersion
AU7106996A (en) † 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
KR100561788B1 (ko) 1996-03-12 2006-09-20 피지-티엑스엘 컴파니,엘.피. 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치
AU3483497A (en) * 1996-06-28 1998-01-21 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
PL195323B1 (pl) 1998-03-17 2007-09-28 Hoffmann La Roche Podstawione bisindolilomaleimidy do hamowania proliferacji komórek

Also Published As

Publication number Publication date
HRP990287B1 (en) 2004-12-31
PL202757B1 (pl) 2009-07-31
EP0988863A3 (en) 2000-08-09
SG97131A1 (en) 2003-07-18
SI0988863T2 (sl) 2009-08-31
TR199902324A2 (xx) 2000-04-21
SI0988863T1 (en) 2004-08-31
CO5140077A1 (es) 2002-03-22
NO994583D0 (no) 1999-09-21
JP2007224048A (ja) 2007-09-06
TWI234465B (en) 2005-06-21
RU2240827C2 (ru) 2004-11-27
HU9903189D0 (en) 1999-11-29
JP6253135B2 (ja) 2017-12-27
AR080892A2 (es) 2012-05-16
ES2218918T5 (es) 2009-06-23
RS50193B (sr) 2009-05-06
BR9904283A (pt) 2000-09-26
HK1026632A1 (en) 2000-12-22
CA2282906A1 (en) 2000-03-22
EP0988863B2 (en) 2009-03-18
HUP9903189A3 (en) 2009-07-28
CA2282906C (en) 2010-07-20
CZ300215B6 (cs) 2009-03-18
JP2016196515A (ja) 2016-11-24
ID24034A (id) 2000-07-06
JP2015187170A (ja) 2015-10-29
HU228341B1 (en) 2013-03-28
HUP9903189A2 (hu) 2000-06-28
JP6534979B2 (ja) 2019-06-26
JP2013035875A (ja) 2013-02-21
PL335592A1 (en) 2000-03-27
NO326928B1 (no) 2009-03-16
DK0988863T4 (da) 2009-06-08
AU4880799A (en) 2000-03-23
PT988863E (pt) 2004-07-30
HRP990287A2 (en) 2000-06-30
ATE265232T1 (de) 2004-05-15
ES2218918T3 (es) 2004-11-16
NZ337884A (en) 2001-02-23
KR100362019B1 (ko) 2002-11-23
YU47399A (es) 2002-08-12
US6350786B1 (en) 2002-02-26
DE69916733T3 (de) 2009-09-24
MY124377A (en) 2006-06-30
AU770745B2 (en) 2004-03-04
IL131957A0 (en) 2001-03-19
EP0988863B1 (en) 2004-04-28
IL131957A (en) 2005-06-19
DK0988863T3 (da) 2004-08-30
TR199902324A3 (tr) 2000-04-21
CZ330499A3 (cs) 2000-04-12
CN1201821C (zh) 2005-05-18
MA26692A1 (fr) 2004-12-20
CN1251312A (zh) 2000-04-26
NO994583L (no) 2000-03-23
DE69916733T2 (de) 2005-03-31
DE69916733D1 (de) 2004-06-03
JP2000095708A (ja) 2000-04-04
AR022096A1 (es) 2002-09-04
EP0988863A2 (en) 2000-03-29
KR20000023426A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
PE20001049A1 (es) Complejos estables de compuestos escasamente solubles
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
CY1120513T1 (el) Υψηλης συμπυκνωσης συνθεση μινοξιδιλης
ES2178268T3 (es) Formulaciones de liberacion controlada.
CA1206418A (en) Antiinflammatory composition for external use
ES2561108T3 (es) Composiciones inyectables para la liberación controlada de compuesto farmacológicamente activo
PT739197E (pt) Composicoes de farmacos oftalmicos conservados contendo compostos de amonio quaternario polimericos
MXPA04011584A (es) Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
DK158335B (da) Fremgangsmaade til fremstilling af farmaceutiske praeparater til ekstern anvendelse og indeholdende et ikke-steroidt antiphlogistisk analgetisk middel
TR200103474T2 (tr) Bileşimlerin anti-bakteriyel madde olarak yeni kullanımları
CO4890859A1 (es) Granulado para la preparacion de composiciones de rapida desintegracion y disolucion que contiene una elevada canti- dad de farmaco
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
KR101304982B1 (ko) 경피흡수용 조성물 및 이로부터 형성된 고분자 매트릭스함유 경피흡수제제
AR036096A1 (es) Formulacion farmaceutica de sabor enmascarado, un procedimiento para su preparacion y un procedimiento de enmascaramiento del sabor de productos farmaceuticos
HK1056318A1 (en) Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent.
TR200201103T2 (tr) İkame edilmiş benzimidazol formülasyonları
BR0208306A (pt) Composições farmacêuticas
ES2460967T3 (es) Método para la prevención de la degradación de una sustancia térmicamente inestable
ITMI20071724A1 (it) Formulazioni topiche antivirali in forma di gel bioadesivo
AR044054A1 (es) Sales de risperidona solubles en agua
ES2375784B1 (es) Gel de ácido tranexámico
CZ409198A3 (cs) Místní gelový prostředek a jeho použití
ITMI20121316A1 (it) Complessi di condroitina ad assorbimento transcutaneo
PT1938820E (pt) Preparação líquida para aplicação externa contendo indometacina
Zhang et al. Reversing the Cytotoxicity of Bile Acids by Cyclodextrin-based Supramolecular Assembly

Legal Events

Date Code Title Description
FC Refusal
MK Expiration of term